Jacqueline Tonks enjoys using technology. At age 78, she’s learned from her grandchildren and children, and is a frequent user of Facebook, Skype and texting. So when she heard about a mobile app that could help her manage her breast cancer treatment, she downloaded it.
“The nice thing about this app is that when I turn on my iPhone or iPad, the app appears and reminds me of things to do today. I really like the reminders of what exercises I’m supposed to do, in what order, and how many. It keeps me on track,” Tonks says. Continue reading →
mCancerPartner interviewed Dan Hayes, M.D., clinical director of the Cancer Center’s breast oncology program. In late September 2015, investigators – including Dr. Hayes – showed that many women with early stage breast cancer can skip chemotherapy with good results, based on a gene test assessing which tumors were more likely to respond to chemotherapy. This study validates clinical recommendations in place since 2007 made by the American Society of Clinical Oncology and the National Comprehensive Cancer Network. Dr. Hayes served on both recommendation task forces and provided the following remarks on the origin of these recommendations.
mCancerPartner: How has the standard of care for women with the most common type of breast cancer (early stage, hormone positive, HER2 negative, not spread to lymph nodes) evolved over the years? Continue reading →
The FDA has approved Opdivo® (Nivolumab) and Keytruda® (Pembrolizumab) to treat patients with advanced non-small cell lung cancer. Both medicines stimulate a patient’s own immune system to destroy cancer cells.
Lung cancer is the leading cause of cancer death in the United States, with an estimated 224,210 new diagnoses in 2014. The most common type of lung cancer, non-small cell lung cancer or NSCLC, affects seven out of eight lung cancer patients.
In October 2015, the U.S. Food and Drug Administration approved Opdivo® (Nivolumab) and Keytruda® (Pembrolizumab) to treat patients with advanced, or metastatic, NSCLC. Both medicines stimulate a patient’s own immune system to destroy cancer cells.
In a pathology report, the diagnosis section provides the location of the tumor, its type and grade, and size.
Chances are, the treatment plan for your cancer was determined by the results on a pathology report. Before your diagnosis, you probably had a biopsy or surgery where a doctor removed cells or tissue for study under a microscope. Specialists called pathologists spend their days viewing these samples, understanding how they look compared to normal cells and preparing reports which summarize the findings on each biopsy for oncologists and surgeons.
We spoke with Cancer Center pathologist, Celina Kleer, M.D., director of the Breast Pathology Division in the Department of Pathology,to find out the information contained in a report and how your oncologist uses it to decide the best course of treatment for your cancer. Continue reading →
After being diagnosed with cancers of the palate and thyroid one after another, professional singer Jerry Garcia knew he was going to have to risk his career in order to save his health and family life.
With surgery recommended for both tumors, Garcia knew at every turn that he might have to take his musical ministry in another direction if surgical complications made him no longer able to sing in the caliber he’d built a career on. Instead, Jerry credits the quality of his recent album – he calls it the best he’s ever sung – to the surgeries and experts he saw at the U-M Health System.
“I came out of this unscathed with no vocal cord damage whatsoever,” Garcia said. “It’s the power of a strong positive attitude.”
NOTICE: Except where otherwise noted, all articles are published under a Creative Commons Attribution 3.0 license. You are free to copy, distribute, adapt, transmit, or make commercial use of this work as long as you attribute the University of Michigan Health System as the original creator and include a link to this article.